Jiangsu Hengrui Medicine (China)

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression

PURPOSE Systemic treatment options for advanced salivary gland carcinoma (SGC) are limited, and prospective data for human epidermal growth factor receptor 2 (HER2)–directed therapy remain sparse, particularly in HER2-low disease. We evaluated trastuzumab rezetecan (SHR-A1811), a...

An ELISA‐Inspired Self‐Propagating Click‐Fluoresce‐and‐Release Assay for the Ultrasensitive Detection of CD13 in Lung Cancer Patient Plasma

ABSTRACT Reaction‐based fluorescent probes often suffer from limited sensitivity in biomarker detection due to slow reaction kinetics and inherent stoichiometric constraints. Inspired by the decoupling of capture and detection in the enzyme‐linked immunosorbent assay (ELISA), we...

An ELISA‐Inspired Self‐Propagating Click‐Fluoresce‐and‐Release Assay for the Ultrasensitive Detection of CD13 in Lung Cancer Patient Plasma

ABSTRACT Reaction‐based fluorescent probes often suffer from limited sensitivity in biomarker detection due to slow reaction kinetics and inherent stoichiometric constraints. Inspired by the decoupling of capture and detection in the enzyme‐linked immunosorbent assay (ELISA), we...